SUBSTITUTED QUINAZOLINONES

Abstract: According to the present invention, there are provided compounds of the formula wherein R₂ is hydrogen, C₁-C₆ alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl and bicycloalkyl; R₆ is C₁-C₆ alkyl; and R₇ is hydrogen, provided that R₇ is hydrogen only when the 3,4-imine linkage is saturated. The compounds of the present invention are useful for the treatment of cardiotonic disorders.

Description: The present invention relates to substituted quinazolinones. According to the present invention, there are provided compounds of the formula wherein R₂ is hydrogen, C₁-C₆ alkyl, C₄-C₈ cyclo­ alkyl, C₄-C₈ cycloalkyl -C₁-C₃ alkyl, C₁-C₄ haloalkyl having 1 to 3 halogen atoms and bicycloalkyl such as norbornyl and norbornylmethyl; R₆ is C₁-C₆ alkyl; and R₇ is hydrogen, provided that R₇ is hydrogen only when the 3,4-imine linkage is saturated. Compounds provided by the present invention which are of particular interest are the following: 5,6-dimethoxy-4-methyl-2(1H)quinazolinone; 3,4-dihydro-5,6-dimethoxy-4-methyl-2(1H)quinazol­ inone; and 5,6-dimethoxy-2(1H) quinazolinone. The invention also includes pharmaceutical compositions containing a compound in accordance with the invention and a pharmaceutically acceptable carrier. The invention further includes medicinal products comprising an effective amount of a compound in accordance with the invention in a pharmaceutically acceptable carrier, for use in a method of treating a patient having a cardiotonic disorder. As will be appreciated from the last preceding paragraph, compounds are provided by the present invention which have utility in that they possess cardiotonic activity. Pharmaceutical compositions containing a compound of the present invention as the active ingredient in intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding tech­ niques. The carrier may take a wide variety of forms depending on the form of preparation desired for adminis­ tration, e.g., intravenous, oral or parenteral. In pre­ paring the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations such as, for example, suspen­ sions, elixirs and solutions; or carriers such as starches, sugars, diluents, granulating agents, lubri­ cants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative pur­ poses, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions will generally contain, dosage unit, e.g., tablet, capsule, powder, injection, teaspoon­ ful and the like, from about 15 to about 300 mg/kg and preferably from about 30 to about 200 mg/kg of the active ingredient. The following examples described the invention in greater particularity and are intended to be a way of illustrating but not limiting the invention. Of the eleven Examples which follow, the first eight (Examples I-VIII) are concerned with the preparation of starting materials, and the last three (Examples IX-XI) with the preparation of compounds in accordance with the invention. Thus Example IX obtains a compound with R₂=H, R₆=CH₃ and R₇ absent, by reacting 2-(N-carbethoxyamino)-5,6-dimethoxy­ benzaldehyde with ammonia/ammonium-acetate. Example X converts this into a 3,4-dihydro compound with R₂=CH₃, R₆=CH₃ and R₇=H; and Example XI converts this in turn into a compound with R₂=CH₃ (or trifluoromethyl, isopropyl or cyclohexyl), R₆=CH₃ and R₇ absent. Example I 2-Hydroxy-3-methoxybenzaldehyde-2-benzenesulfonate A slurry of 3-methoxysalicylaldehyde (45.6 g, 299 mM) in NaOH (138 ml, 15% aqueous solution) is treated with benzenesulfonyl chloride (66 g, 373 mM) and the mixture vigorously stirred for 1 hour. The reaction mixture is then poured into ice-water (500 ml) and the resulting white solid filtered, washed with cold water, and then recrystallized from acetic acid to afford the product as a white solid; yield 72.2 g (85%); m.p. 119-120°C. Example II 2-Hydroxy-3-methoxy-6-nitrobenzaldehyde-2-­ benzenesulfonate 2-Hydroxy-3-methoxybenzaldehyde-2-benzenesulfonate (50 g, 171 mM) is added to nitric acid (500 ml) at 0°C - 5°C. The solution is kept five minutes at 5°C and then poured into ice-water (1.5 L). The crude product, a tan solid, is filtered, washed with cold water, alcohol, and then recrystallized from acetic acid (650 ml) to afford the product as a white solid; yield 30.3 g (52.6%); m.p. 152-­ 154°C. Example III 2-Hydroxy-3-methoxy-6-nitrobenzaldehyde A slurry of 2-hydroxy-3-methoxy-6-nitrobenzaldehyde-2-­ benzenesulfonate (10.12 g, 30 mM) in methanol (120 ml) is heated to reflux. A solution of KOH (6 g) in water (24 ml) and methanol (12 ml) is added and the two phase mixture refluxed for 30 minutes. The light reddish preci­ pitate which forms is filtered and then dissolved in boiling water (120 ml). Acidification of the hot aqueous solution with 10% aqueous HCl to pH∼ 4 gives a yellow precipitate (5.0 g). Recrystallization from isopropyl alcohol affords the product as a yellow solid; yield 4.5 g (76.2%); m.p. 102-104°C. Example IV 2,3-Dimethoxy-6-nitrobenzaldehyde A slurry of NaH (16.0 g, 50% oily dispersion, 337 mM) in dimethylformamide (200 ml) was treated dropwise with a solution of 2-hydroxy-3-methoxy-6-nitrobenzaldehyde (49.0 g, 248 mM) in DMF (300 ml) at such a rate that the temperature did not exceed 35°C. The mixture is aged at room temperature for 1 hour and then a large excess of methyl iodide (100 ml) is added dropwise. A slight exothermic reaction occurs. The mixture is then stirred vigorously for 19 hours at room temperature. After the removal of excess methyl iodide, the reaction mixture is poured into ice-water (1 l). The crude product, a brown solid, is filtered, washed with cold water, and then recrystallized from isopropyl alcohol (700 ml) to afford the product as a tan solid; yield 27.9 g (53.3%); m.p. 106-108°C. Example V 2,3-Dimethoxy-6-nitrobenzaldehyde-ethyleneketal A mixture of 2,3-dimethoxy-6-nitrobenzaldehyde (16.0 g, 75 mM), ethylene glycol (64 g, 103 mM), and p -toluenesul­ fonic acid monohydrate (0.2 g) in benzene (750 ml) is refluxed in a Dean-Stark apparatus for 48 hours. The solution is then poured into water (1 l.). The organic phase is washed with saturated aqueous NaHCO₃ (2x20 ml), dried over Na₂SO₄, filtered, and the solvent removed in vacuo . The crude product is recrystallized from n -­ hexane (2 l.); yield 15.2 g (78.2%); m.p. 74-76°C. Example VI 2-Amino-5,6-dimethoxybenzaldehyde ethyleneketal A solution of 2,3-dimethoxy-6-nitrobenzaldehyde-ethylene­ ketal (12.1 g, 62.7 mM) in ethyl acetate (350 ml) contain­ ing sodium acetate (0.5 g) is treated with platinum oxide (1.0 g) and the mixture hydrogenated for 24 hours at ∼50 psi. The solvent is removed in vacuo after filtering off the catalyst to give a pale brown oil. After crystal­ lization from n -hexane, the product is obtained as a tan solid; yield 12.8 g (85.1%); m.p. 78-80°C. Example VII 2-(N-Carbethoxyamino)-5,6-dimethoxybenzaldehyde ethyleneketal Ethylchloroformate (1.9 g, 17.5 mM) is added with stirring to 2-amino-5,6-dimethoxybenzaldehyde-ethyleneketal (1.6 g, 7.1 mM) dissolved in tetrahydrofuran (50 ml). A solution of sodium hydroxide in H₂O (0.72 g in 3.5 ml H₂O) is added and the resulting solution is stirred for 2 hours at room temperature. The tetrahydrofuran is removed in vacuo and the residue extracted with CHCl₃ (2x100 ml). The extracts are dried over Na₂SO₄, filtered, and the solvent removed in vacuo . The crude product is recrystal­ lized from n -hexane; yield 1.2 g (57.1%); m.p. 95-96°C. Example VIII 2-(N-Carbethoxyamino)-5,6-dimethoxybenzaldehyde 2-(N-Carbethoxyamino)-5,6-dimethoxybenzaldehyde-ethylene­ ketal (5.0 g, 16.8 mM) is dissolved in acetone (36 ml) and aqueous HCl (3 ml of 1N solution). The mixture is stirred at room temperature for 4 hours. The solvent is removed in vacuo to give a yellow solid (3.9 g). Recrystalliza­ tion from n -hexane gives the pure product as a yellow solid; yield 3.6 g (84.7%); m.p. 86-88°C. Example IX 5,6-Dimethoxy-2(1H)-quinazolinone A stream of dry ammonia gas is passed through a solution of 2-(N-carbethoxyamino)-5,6-dimethoxybenezaldehyde (12.4 g, 48.9 mM) and ammonium acetate (95 g) maintained at 155-160°C for 3 hours. The reaction mixture is cooled and poured into an ice-water mixture. A tan solid forms. The aqueous mixture is treated with NaCl (50 g) and then extracted with CHCl₃ (3x200 ml). The organic extracts are combined and the solvent is removed in vacuo to yield 9.2 g of a pale brown oil. Trituration of the oil with hot acetone gives the product as a yellow solid; yield 2.1 g (20.8%); m.p. 242-244°C. Example X 3,4-Dihydro-5,6-dimethoxy-4-methyl-2(1H)quinazolinone To a partial solution of 5,6-dimethoxy-2(1H)quinazolinone (10.0 g, 48.5 mM) in dry tetrahydrofuran (1100 ml) under nitrogen, is added at 0°C over 20 minutes, an excess of methyl magnesium bromide in ether (62.60 ml of a 3.1 M solution in ether, 194.06 mM). The reaction mixture is then removed from the cooling bath, allowed to reach room temperature and is stirred at room temperature for 16 hours. Additional methyl magnesium bromide is added (15.65 ml of a 3.1 M solution in ether; 48.52 mM) and the reaction mixture is heated at reflux for 2 hours, cooled in an ice-water bath and an aqueous solution of NH₄Cl (100 ml of saturated NH₄Cl and 100 ml H₂O) is added with stirring. After the addition is complete, 10% aqueous HCl is added until a pH of ∼6.0 is reached. The layers are separated and the aqueous layer is extracted with CHCl₃ (3x250 ml). The CHCl₃ extract is combined with the pre­ viously separated tetrahydrofuran layer, and the combined organic layers are washed with a saturated aqueous solu­ tion of NaCl (200 ml) and dried (Na₂SO₄). Filtration followed by concentration to ∼250 ml affords an off-white precipitate which is filtered and recrystallized from isopropanol (200 ml) to give the product as a colorless solid; yield 9.7 g (87.8%), m.p. 210-212°C. Example XI 5,6-Dimethoxy-4-methyl-2(1H) quinazolinone Potassium permanganate (25.6 g, 162.38 mM) is added to a solution of 3,4-dihydro-5,6-dimethoxy-4-methyl-2(1H)quina­ zolinone (18.04 g, 81.19 mM) in acetone (5.0 liters) and the mixture is stirred at room temperature (under nitro­ gen, protected from light with aluminum foil) for 96 hours. The brown precipitate which forms is filtered and washed with acetone (500 ml) and is partially dissolved in boiling water (1000 ml). The hot. aqueous solution (after filtration) is neutralized with 10% aqueous HCl and then extracted with CHCl₃ (4x250 ml) and 10% isopropyl alcohol/ethyl acetate (4x250 ml). The CHCl₃ extracts are dried (MgSO₄), filtered, and concentrated to 500 ml at which point a solid forms. The solid is filtered off and the filtrate is further concentrated in vacuo to give 3.25 g of a tan solid which is chromatographed on a 350 g SilicAR column that has been prepared in CHCl₃ (500 ml fractions). Elution with 1/2% methanol/chloroform affords a yellow solid (1.92 g) which upon recrystallization from isopropanol (75 ml) affords the product as a yellow solid; yield 0.940 g (5.3%); mp 230-232°C. When in the above procedure 3,4-dihydro-5,6-dimethoxy-4-­ trifluoromethyl-2(1H)quinazolinone, 3,4-dihydro-5,6-­ dimethoxy-4-isopropyl-2(1H)quinazolinone and 3,4-dihydro­ 4-cyclohexyl-5,6-dimethoxy-2(1H)quinazolinone are employed in place of 3,4-dihydro-5,6-dimethoxy-4-methyl-2(1H)quina­ zolinone the corresponding 5,6-dimethoxy-4-trifluoro­ methyl-2(1H)quinazolinone, 5,6-dimethoxy-4-isopropyl-­ 2(1H)quinazolinone and 4-cyclohexyl-5,6-dimethoxy-2(1H)-­ quinazolinone are obtained. The present application is a divisional application derived from our copending European application No. 83305895.1 (Publication No. EP-A-0 107 398).

Claims: 1. A compound of the formula wherein R₂ is hydrogen, C₁-C₆ alkyl, C₄-C₈ cyclo­ alkyl, C₄-C₈ cycloalkyl -C₁-C₃ alkyl, C₁-C₄ haloalkyl having 1 to 3 halogen atoms and bicycloalkyl such as norbornyl and norbornylmethyl; R₆ is C₁-C₆ alkyl; and R₇ is hydrogen, provided that R₇ is hydrogen only when the 3,4-imine linkage is saturated. 2. A compound of Claim 1 which is 5,6-dimethoxy-4-­ methyl-2(1H)quinazolinone. 3. A compound of Claim 1 which is 3,4-dihydro-5,6-­ dimethoxy-4-methyl-2(1H)quinazolinone. 4. A compound of Claim 1 which is 5,6-dimethoxy-­ 2(1H)quinazolinone. 5. A pharmaceutical composition comprising a compound according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier. 6. A compound according to any one of claims 1 to 4 or a composition according to claim 5 for use in treating a patient having a cardiotonic disorder. 7. The process for preparing a compound of the formula which comprises reacting a compound of the formula with ethylene glycol to form the corresponding 2,3-dialkoxy-­ 6-nitrobenzaldehyde-ethyleneketal, reacting the ethyleneketal with a reducing agent to form the corresponding 2-amino-5,6-­ dialkoxybenzaldehyde ethyleneketal, reacting the amino­ benzaldehyde ethyleneketal with ethyl chloroformate to form the corresponding 2-(N-carbethoxyamino) 5,6-dimethoxy­ benzaldehyde ethyleneketal, reacting the 2-(N-carbethoxy­ amino) ethyleneketal with a mineral acid to form the 2-(N-­ carbethoxyamino)-5,6-dimethoxybenzaldehyde, reacting the benzaldehdye with ammonia to form a quinazolinone of the formula reacting the quinazolinone with an alkyl magnesium bromide to form a quinazolinone of the formula and reacting the quinazolinone with an oxidizing agent; wherein R₆ is C₁-C₆ alkyl. 8. The process according to claim 7 wherein R₆ is methyl. 9. The process according to claim 7 or 8 wherein the reducing agent is hydrogen and the oxidizing agent is potassium permanganate. 10. The process according to claim 7, 8 or 9 wherein the mineral acid is hydrochloric acid.

Inventors: BANDURCO VICTOR T, LEVINE SEYMOUR D, MULVEY DENNIS M, TOBIA ALFONSO J, BANDURCO, VICTOR T., LEVINE, SEYMOUR D., MULVEY, DENNIS M., TOBIA, ALFONSO J.
Applicants: ORTHO PHARMA CORP, ORTHO PHARMACEUTICAL CORPORATION
Application year: 1983
Main classification: C07D239
IPC codes: C07D239, C07D317, A61P9, C07D237, C07D401, A61K31, C07C275, A61P13